|
|
Man-TLR7 |
|
Vaxjo ID |
256 |
|
Vaccine Adjuvant Name |
Man-TLR7 |
|
Alternative Names |
mannose + TLR7 agonist copolymer |
|
Adjuvant VO ID |
VO_0005743
|
|
Description |
A synthetic random copolymer with monomers bearing mannose (to target dendritic cells) and TLR7 agonists (to activate innate immunity). It’s covalently conjugated to antigens (e.g., SARS-CoV-2 Spike protein or RBD) to form subunit vaccine conjugates (e.g., Spike-p(Man-TLR7)) |
|
Stage of Development |
Research |
|
Host Species for Testing |
3 |
|
Components |
synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antigens, elicits robust humoral and cellular immunity |
|
Structure |
Random copolymer made by RAFT polymerization of: Mannose-bearing monomer TLR7 agonist-bearing monomer Inert HPMA backbone |
|
Storage |
Stable at 4 °C and −20 °C for over 9 months, withstanding ≥5 freeze-thaw cycles |
|
Preparation |
Antigens (Spike or RBD) conjugated to p(Man-TLR7) via self-immolative PEG linkers Conjugation confirmed by SDS-PAGE Prepared using endotoxin-free procedures |
|
Dosage |
Each mouse received: 10 µg antigen (Spike or RBD) 20 µg TLR7 content from p(Man-TLR7) With or without 50 µg alum |
|
Function |
The core of the vaccine platform is the copolymer p(Man-TLR7), composed of monomers with pendant mannose or a toll-like receptor 7 (TLR7) agonist. |
|
Safety |
No complement activation (CARPA) observed Good tolerability in mice; no signs of toxicity |
| References |
Gray et al., 2021: Gray LT, Raczy MM, Briquez PS, Marchell TM, Alpar AT, Wallace RP, Volpatti LR, Sasso MS, Cao S, Nguyen M, Mansurov A, Budina E, Watkins EA, Solanki A, Mitrousis N, Reda JW, Yu SS, Tremain AC, Wang R, Nicolaescu V, Furlong K, Dvorkin S, Manicassamy B, Randall G, Wilson DS, Kwissa M, Swartz MA, Hubbell JA. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Biomaterials. 2021; 278; 121159. [PubMed: 34634664].
|
|
